Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
TEM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.36 - $91.45
Previous CloseN/A
Volume1.41M
Average Volume (3M)10.78M
Market Cap
$13.18B
Enterprise Value$11.58B
Total Cash (Recent Filing)$291.31M
Total Debt (Recent Filing)$853.25M
Price to Earnings (P/E)―
Beta3.17
Next Earnings
Nov 06, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding168,683,760
10 Day Avg. Volume11,273,483
30 Day Avg. Volume10,782,633
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue12.16
Enterprise Value/Gross Profit19.46
Enterprise Value/Ebitda-66.47
Forecast
1Y Price Target
$73.82Price Target Upside-2.69% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Business DevelopmentTempus works with 19 of the top 20 pharma companies, highlighting its strong industry connections.
Revenue GrowthTempus raised its FY'25 revenue guide by $10M, which looks conservative given the expected lift in data services.
Strategic PartnershipsLarge recent $200M deal with AZN underscores the value of its data asset.
Bears Say
Operational ChallengesThe lack of quarterly bookings, reliance upon Pathos (a related party relationship) for growth & flattish Performance Obligations (ex Pathos) are drawbacks.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $31.36 and its highest was $91.45 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $13.18B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Nov 06, 2025 which is in 64 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Aug 08, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.01.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Overvalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.17.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 168,683,760 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 3.626%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
Tempus AI, Inc. Class A Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.82 (-2.69% Downside)
$73.82 (-2.69% Downside)
Blogger Sentiment
Bullish
TEM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 643.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.99%
12-Months-Change
Fundamentals
Return on Equity
-97.95%
Trailing 12-Months
Asset Growth
87.99%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, improvement in adjusted EBITDA, and strong performance in oncology and hereditary testing. The company also made successful financing and signed a large data and AI deal, positioning them well for the future. However, there are challenges in achieving reimbursement for the MRD portfolio and pressure on ASP growth due to product mix shifts.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$73.82
▼(-2.69% Downside)
Technical Analysis
Ownership Overview
42.73% Insiders
6.17% Mutual Funds
0.11% Other Institutional Investors
39.96% Public Companies and Individual Investors